Solaris Resources Inc. (CVE:SLS – Free Report) – Equities research analysts at HC Wainwright reduced their FY2024 EPS estimates for Solaris Resources in a research note issued to investors on Monday, November 18th. HC Wainwright analyst H. Ihle now forecasts that the company will post earnings of ($0.56) per share for the year, down from their prior estimate of ($0.45). HC Wainwright has a “Strong-Buy” rating on the stock. HC Wainwright also issued estimates for Solaris Resources’ FY2025 earnings at ($0.44) EPS.
Solaris Resources Trading Down 2.7 %
CVE:SLS opened at C$6.15 on Wednesday. The company has a 50-day moving average price of C$6.15. Solaris Resources has a 1-year low of C$1.38 and a 1-year high of C$7.09.
Solaris Resources Company Profile
SELLAS Life Sciences Group, Inc, a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
Featured Stories
- Five stocks we like better than Solaris Resources
- Investing In Automotive Stocks
- Why Palo Alto Networks’ Multi-Year Uptrend Is Far From Over
- 3 Ways To Invest In Coffee, Other Than Drinking It
- 3 Rock-Solid Buying Opportunities in the Market Right Now
- Technology Stocks Explained: Here’s What to Know About Tech
- TJX Companies Stock Poised to Hit a New High This Year
Receive News & Ratings for Solaris Resources Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solaris Resources and related companies with MarketBeat.com's FREE daily email newsletter.
